Table 2.
Serotypes, resistance patterns, and phenotypic and genotypic characterization of Pseudomonas aeruginosa isolates.
| Isolate | Serotype | Minimum inhibitory concentration (mg/L)a | Genotypic profile | PFGE type | Plasmid | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPM | MER | DOR | CAZ | CIP | TM | CS | AN | ATM | TIC | |||||
| 1 | O:11 | 128 | 64 | 64 | >256 | >16 | >128 | 1 | 128 | 16 | >1,024 | IMP-7, OXA-10, VIM-11 | A | No |
| 2 | O:11 | 32 | 64 | 32 | >256 | >16 | >128 | 2 | 128 | 16 | >1,024 | IMP-7, OXA-10, VIM-11 | A | No |
| 3 | O:11 | 128 | 128 | 64 | >256 | >16 | 128 | 1 | 32 | 16 | >1,024 | IMP-7, OXA-10, VIM-11 | A | No |
| 4 | O:11 | >256 | >128 | >128 | >256 | >16 | 64 | 1 | 16 | 16 | >1,024 | IMP-7, OXA-10, VIM-2 | B | No |
| 5 | O:11 | >256 | >128 | >128 | 128 | 0.5 | >128 | 2 | 32 | 8 | >1,024 | VIM-4, IMP-7, OXA-2 | C | No |
| 6 | O:11 | >256 | >128 | >128 | 256 | 0.5 | 1 | 1 | 64 | 8 | >1,024 | VIM-4, IMP-7, OXA-2 | C | No |
| 7 | O:11 | >256 | >128 | 128 | 128 | >16 | >128 | 8 | 256 | 32 | >1,024 | VIM-4, IMP-7, OXA-2 | D | No |
| 8 | O:7 | 64 | 64 | 32 | 256 | >16 | >128 | 2 | 128 | 8 | >1,024 | VIM-28 | E | >50 kb |
| 9 | NT | 128 | 128 | 64 | >256 | >16 | 64 | 2 | >256 | >512 | >1,024 | OXA-10, VEB-1a, GES-4, VIM-1 | A | No |
| 10 | O:4 | 16 | 16 | 4 | >256 | >16 | 64 | 2 | >256 | 128 | >1,024 | IMP-7, OXA-10, VIM-11 | A | No |
| 11 | O:15 | 32 | 32 | 32 | >256 | >16 | 128 | 2 | 64 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 12 | O:15 | 32 | 32 | >128 | >256 | >16 | 128 | 2 | 32 | 512 | 1,024 | OXA-10, VEB-1a | F | 50 kb |
| 13 | O:15 | 32 | 32 | 16 | >256 | >16 | >128 | 2 | 128 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 14 | O:15 | 32 | 32 | 16 | >256 | >16 | 64 | 1 | 32 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 15 | O:15 | 32 | 32 | 8 | >256 | >16 | 64 | 1 | 32 | >512 | 1,024 | OXA-10, VEB-1a | F | 50 kb |
| 16 | O:15 | 32 | 32 | 16 | >256 | >16 | 128 | 2 | 64 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 17 | O:15 | 32 | 128 | 64 | >256 | >16 | 64 | 1 | 32 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 18 | O:15 | >256 | 128 | 64 | >256 | >16 | 64 | 2 | 32 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 19 | O:15 | 32 | 32 | 16 | >256 | >16 | 128 | 2 | 32 | >512 | >1,024 | OXA-10, VEB-1a | F | 50 kb |
| 20 | O:11 | 128 | 128 | 128 | >256 | >16 | 64 | 1 | 32 | 16 | >1,024 | IMP-7 | G | No |
| 21 | O:11 | 16 | 32 | 32 | >256 | >16 | 64 | 1 | 16 | 8 | 512 | IMP-7 | H | No |
| 22 | O:11 | 16 | 32 | 16 | >256 | >16 | 32 | 2 | 16 | >512 | >1,024 | VEB-1b, OprD−, MexAB+ | I | No |
| 23 | O:11 | 16 | 16 | 4 | >256 | >16 | 64 | 2 | 64 | >512 | 1,024 | VEB-1b, OprD−, MexAB+ | J | No |
| 24 | O:11 | 16 | 16 | 8 | >256 | >16 | 64 | 2 | 32 | 512 | 1,024 | VEB-1b | J | No |
| 25 | O:11 | >256 | 32 | 16 | >256 | >256 | 64 | 2 | 64 | 256 | >1,024 | VEB-1b, OprD− | J | No |
| 26 | O:11 | 16 | 16 | 4 | >256 | >16 | 32 | 2 | 32 | >512 | >1,024 | VEB-1b | J | No |
| 27 | O:11 | 13 | 8 | 4 | >256 | >16 | 32 | 2 | 32 | 512 | 1,024 | VEB-1b | J | No |
| 28 | O:4 | 32 | 32 | 2 | 128 | 4 | 128 | 1 | 16 | 16 | >1,024 | GES-1, OprD− | K | No |
| 29 | O:4 | 128 | 128 | 64 | 256 | >16 | 64 | 2 | >256 | 32 | 1,024 | GES-6 | L | No |
| 30 | O:10 | 16 | 16 | 8 | 32 | 0.3 | 1 | 2 | 4 | 512 | 256 | OprD− | M | No |
| 31 | O:4 | 32 | 16 | 8 | 64 | 0.5 | 1 | 1 | 4 | 64 | 256 | OprD−, MexAB+ | N | No |
| 32 | O:10 | 8 | 8 | 8 | 64 | 0.3 | 1 | 2 | 2 | 64 | 64 | OprD− | N | No |
| 33 | O:11 | 64 | 32 | 32 | 64 | 1 | 1 | 1 | 8 | 64 | 128 | OprD−, MexAB+ | N | No |
| 34 | O:1 | 32 | 16 | 4 | 8 | 1 | 64 | 2 | 8 | 16 | >1,024 | OprD−, PSE-1, MexAB+ | N | No |
aMinimum inhibitory concentration interpretation according to CLSI (2014) recommendations [20].
IPM: imipenem; MER: meropenem; DOR: doripenem; CAZ: ceftazidime; AN: amikacin; TM: tobramycin; CIP: ciprofloxacin; CS: colistin; ATM: aztreonam; TIC: ticarcillin.
NT: nontypable.
OprD−: downregulation of OprD porin.
MexAB+: upregulation of MexAB.